DIMOND.

Methods	12‐week, randomised, double‐blind, parallel study.
Participants	90 HD patients (clinical features of HD and a confirmatory family history of HD, and/or genetically confirmed HD), able to take medication (capsules) by mouth. Exclusion criteria: unstable medical illness, pregnant or lactating women of those intending to become pregnant during the study period.
Interventions	Dimebon 60 mg/day vs placebo.
Outcomes	Primary: safety and tolerability. Secondary endpoint: efficacy on cognitive, motor, and overall function in subjects with Huntington's Disease. Assess the pharmacokinetics of Dimebon.
Notes